Answers are grounded in this paper and cite their sources.
Prostate cancer (PC) currently occupies a leading position in Western countries in terms of morbidity and mortality among all tumor diseases. Prostate cancer appears in the form of adenocarcinoma (localized PC), which can remain indefinitely in a dormant form that does not threaten the life of the patient, or transform into an aggressive cancer that is insensitive to androgen-deprivation therapy—castration-resistant prostate cancer (CRPC) with metastasis and rapid lethal outcome. PC arises from the epithelium of the prostate gland, the formation and functioning of which occurs under the action of androgens. Androgens, mainly dihydrotestosterone, activate the androgen-receptor (AR) signaling pathway, which regulates the growth and division of the prostate epithelium under normal conditions and in localized PC. Androgen-deprivation therapy, for example, with androgen-receptor inhibitors (enzalutamide or abiraterone), inhibits the development of localized PC for 1.5–2 years, but then loses its effectiveness and inevitably leads to the transition of the disease to aggressive CRPC. Inactivation of the tumor suppressor RB contributes to the development of cancer of any tissue specificity due to mutations, gene loss, or posttranslational modification of its product. Assessment of the state of RB and its product shows that RB gene is altered in less than 1% of patients with localized PC, but its loss causes CRPC in 17–33% of patients. This brief literature review presents the role of the pRb signaling pathway in the pathogenesis of localized and castration-resistant PC.
No takes yet. Share an insight, caveat, or question.
Ryabov et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: